The	O
role	O
of	O
IGF	B:C0021665
-	I:C0021665
1	I:C0021665
and	O
the	O
distribution	O
of	O
body	B:C0344335
fat	I:C0344335
in	O
decreasing	B:C0442797
the	O
number	O
of	O
prostate	B:C0194804
rebiopsies	I:C0194804
.	O

To	O
assess	O
the	O
usefulness	O
of	O
IGF	B:C0021665
-	I:C0021665
1	I:C0021665
and	O
internal	B:C0344335
organ	I:C0344335
fat	I:C0344335
measured	O
by	O
bioelectrical	B:C0162536
impedance	I:C0162536
audiometry	B:C0004286
to	O
avoid	O
rebiopsies	B:C0005558
in	O
patients	O
with	O
persistently	O
high	B:C4293696
prostate	I:C4293696
-	I:C4293696
specific	I:C4293696
antigen	I:C4293696
(	I:C4293696
PSA	I:C4293696
)	I:C4293696
levels	I:C4293696
.	O

A	O
prospective	B:C0033522
study	I:C0033522
was	O
conducted	O
with	O
92	O
patients	O
who	O
underwent	O
prostate	B:C0194804
rebiopsy	I:C0194804
due	O
to	O
high	O
PSA	O
levels	O
with	O
negative	B:C1334932
results	I:C1334932
in	O
the	O
rectal	B:C0199900
examination	I:C0199900
and	O
a	O
lack	O
of	O
preneoplastic	B:C0282313
lesions	B:C0221198
.	O

The	O
patients	O
previously	O
had	O
their	O
IGF	B:C0021665
-	I:C0021665
1	I:C0021665
levels	O
measured	O
and	O
had	O
undergone	O
an	O
impedance	B:C0001161
audiometry	I:C0001161
test	I:C0001161
using	O
the	O
abdominal	B:C0000726
Fat	B:C0025080
Analyser	I:C0025080
AB	I:C0025080
-	I:C0025080
140	I:C0025080
TANITA	I:C0025080
system	I:C0025080
.	O

We	O
calculated	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
for	O
the	O
PSA	B:C0428540
levels	I:C0428540
,	O
%	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
internal	B:C0344335
organ	I:C0344335
fat	I:C0344335
and	O
IGF	B:C0021665
-	I:C0021665
1	I:C0021665
and	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
density	O
.	O

Twenty	O
-	O
five	O
patients	O
were	O
diagnosed	B:C0011900
with	O
prostate	B:C0600139
cancer	I:C0600139
.	O

These	O
patients	O
had	O
significantly	O
higher	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
PSAd	B:C0138741
and	O
IGF	B:C0021665
-	I:C0021665
1	I:C0021665
values	O
and	O
a	O
tendency	O
towards	O
higher	O
internal	B:C0344335
organ	I:C0344335
fat	I:C0344335
levels	O
and	O
lower	B:C0441994
%	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
readings	O
(	O
p=.001	O
,	O
p=.003	O
,	O
p=.001	O
,	O
p=.24	O
and	O
P=0.28	O
,	O
respectively	O
)	O
.	O

The	O
ROC	O
curve	O
showed	O
an	O
area	B:C0205146
under	O
the	O
curve	O
for	O
IGF	B:C0021665
-	I:C0021665
1	I:C0021665
and	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
of	O
.82	O
and	O
.81	O
,	O
respectively	O
.	O

Using	O
the	O
cutoff	O
points	O
for	O
95	O
%	O
sensitivity	O
and	O
using	O
the	O
3	O
criteria	O
as	O
an	O
indication	O
of	O
rebiopsy	B:C0005558
,	O
74	O
%	O
of	O
the	O
biopsies	B:C0005558
would	O
have	O
been	O
spared	O
,	O
leaving	O
undiagnosed	B:C1408353
only	O
1	O
patient	O
with	O
clinically	O
significant	O
cancer	B:C0006826
-	O
Gleason	B:C3203027
score	I:C3203027
>	O
7	O
(	O
4+3	O
)	O
-	O
.	O

The	O
cost	O
of	O
both	O
determinations	B:C1148554
was	O
82	O
euros	O
.	O

Our	O
results	O
suggest	O
that	O
measuring	O
IGF	B:C0021665
-	I:C0021665
1	I:C0021665
could	O
significantly	O
decrease	O
the	O
number	O
of	O
unnecessary	B:C0376708
rebiopsies	B:C0005558
in	O
an	O
inexpensive	O
and	O
safe	O
manner	O
.	O

